Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPD | P32754 | 2/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | LITAF | Q99732 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639758 | 0.89 | LMNA (0.45) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL2333544 | 0.84 | LMNA (0.52) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL1546128 | 0.82 | LMNA (0.46) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL2756837 | 0.79 | LMNA (0.51) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL240142 | 0.79 | LMNA (0.51) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL4639746 | 0.77 | LMNA (0.49) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL1945158 | 0.76 | LMNA (0.45) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL8188866 | 0.76 | LMNA (0.45) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL2543060 | 0.76 | LMNA (0.45) | LMNASMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL1945918 | 0.75 | LMNA (0.56) | LMNASMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304070-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | LMNA 3677/4885SMN1; SMN2 2102/4885HPGD 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.